Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Screening auf Prostatakrebs bei älteren Patienten (PLCO-Screening-Studie)

17. November 2026 aktualisiert von: National Cancer Institute (NCI)

Studie zur Früherkennung von Prostata-, Lungen-, Darm- und Eierstockkrebs (PLCO).

This clinical trial studies whether screening methods used to diagnose cancer of the prostate, lung, colon, rectum, or ovaries can reduce deaths from these cancers. Screening tests may help doctors find cancer cells early and plan better treatment for prostate cancer.

Studienübersicht

Status

Aktiv, nicht rekrutierend

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

PRIMARY OBJECTIVES:

I. To determine whether screening with digital rectal examination (DRE) plus serum prostate-specific antigen (PSA) can reduce mortality from prostate cancer in men aged 55-74 at entry.

SECONDARY OBJECTIVES:

I. To assess screening variables, other than mortality, for each of the interventions including sensitivity, specificity, and positive predictive value.

II. To assess the incidence, stage, and survival of cancer cases. III. To investigate the mortality predictive value of biologic and/or prognostic characterizations of tumor tissue as intermediate endpoints.

IV. To conduct biomolecular and genetic research into factors associated with cancer carcinogenesis and promotion, as well as the early detection of these factors.

OUTLINE: Participants in the overall PLCO study are stratified by screening center, gender, and age (55-59 vs 60-64 vs 65-69 vs 70-74). Participants are randomized to 1 of 2 arms (control vs screening).

ARM I (Control): Participants receive standard medical care. Participants complete a Diet History Questionnaire (DHQ) at baseline.

ARM II (Prostate Screening): Participants undergo blood sample collection for PSA analysis at baseline and annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo a DRE at baseline and annually for 3 years. A scheduling and tracking procedure is implemented to ensure regular attendance at repeat screens for participants screened negative or for those who are designated suspicious or positive at screening but for whom subsequent diagnostic procedures do not reveal prostate cancer (follow-up diagnostic procedures are through their own medical care environment). Participants diagnosed with prostate cancer via a screening test are referred for treatment in accordance with current accepted practice for appropriate stage of disease, patient age, and medical condition; a procedure is provided for contact with qualified medical personnel to insure appropriate therapy.

Participants complete a Dietary Questionnaire (DQX) at baseline and DHQ at year 3. An Annual Study Update (ADU) (previously referred to as the Periodic Survey of Health [PSH] questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident prostate cancers as all deaths that occur among both screened and control subjects during the trial.

After completion of screening, participants are followed up for at least 13 years.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

76685

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Maryland
      • Bethesda, Maryland, Vereinigte Staaten, 20892
        • National Institutes of Health Clinical Center

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

55 Jahre bis 74 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Männlich

Beschreibung

Exclusion Criteria:

  • Men who at the time of randomization are less than 55 or greater than or equal to 75 years of age

  • Individuals undergoing treatment for cancer at this time, excluding basal-cell and squamous-cell skin cancer

  • Individuals with known prior cancer of the colon, rectum, lung, prostate

    • This includes primary or metastatic PLCO cancers
  • Individuals with previous surgical removal of the entire colon, one lung, or the entire prostate

  • Individuals who are participating in another cancer screening or cancer primary prevention trial

  • Males who have taken Proscar/Propecia/finasteride in the past 6 months

    • NOTE: Individuals who are already enrolled in the trial when their physician prescribes finasteride are not prevented from taking this medication. As a result, these participants will continue to be screened and followed just as those participants who are not on finasteride.
    • NOTE: Men who are taking Tamoxifen are not excluded from any part of the PLCO Screening Trial.
  • Individuals who are unwilling or unable to sign the informed consent form

  • Males who have had more than one PSA blood test in the past three years

  • Individuals who have had a colonoscopy, sigmoidoscopy, or barium enema in the past three years

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Screening
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Kein Eingriff: Control

Participants receive standard medical care. Participants complete a DHQ at baseline.

Aktiver Komparator: Prostate Screening

Participants undergo blood sample collection for PSA analysis at baseline and annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo a DRE at baseline and annually for 3 years. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident prostate cancers as all deaths that occur among both screened and control subjects during the trial.

Correlative studies

Undergo questionnaire assessments

Undergo DRE

Andere Namen:
  • Prüfung
  • Untersuchung
  • Medizinisches Gutachten
  • Medizinische Untersuchung
  • Medizinische Inspektion
  • Gesundheitsbewertung
  • Beurteilung des Gesundheitszustands
  • Gesundheitsuntersuchung

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Prostate Cancer Deaths
Zeitfenster: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.

Prostate cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.
Prostate Cancer Death Rates
Zeitfenster: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.

Prostate cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. Rate is the number of deaths divided by person years of follow-up in the study.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Complications of Diagnostic Evaluation (DE) Following a Positive Screening Test
Zeitfenster: One year from screening examination

Number of positive screens with complications

One year from screening examination
Deaths From All Causes
Zeitfenster: Events through 13 years of follow-up or through December 31, 2009.

Deaths from all causes were compared between the prostate cancer screening arm and the usual care arm.

Events through 13 years of follow-up or through December 31, 2009.
Death Rates From All Causes
Zeitfenster: Events through 13 years of follow-up or through December 31, 2009.

Deaths from all causes were compared between the prostate cancer screening arm and the usual care arm. Rate is the number of deaths divided by person years of follow-up in the study.

Events through 13 years of follow-up or through December 31, 2009.
Prostate Cancer Incidence
Zeitfenster: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.

Prostate cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as prostate cancer diagnoses divided by person years at risk for prostate cancer.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.
Prostate Cancer Incidence Rates
Zeitfenster: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.

Prostate cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as prostate cancer diagnoses divided by person years at risk for prostate cancer.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.
T0 (Baseline) PSA Screening Results
Zeitfenster: T0 (at study entry)

Prostate-Specific Antigen (PSA) result.

T0 (at study entry)
T0 (Baseline) DRE Screening Results
Zeitfenster: T0 (at study entry)

Digital Rectal Examination (DRE) result.

T0 (at study entry)
T1 PSA Screening Results
Zeitfenster: T1 (one year after entry)

Prostate-Specific Antigen (PSA) result.

T1 (one year after entry)
T1 DRE Screening Results
Zeitfenster: T1 (one year after entry)

Digital Rectal Examination (DRE) result.

T1 (one year after entry)
T2 PSA Screening Results
Zeitfenster: T2 (two years after entry)

Prostate-Specific Antigen (PSA) result.

T2 (two years after entry)
T2 DRE Screening Results
Zeitfenster: T2 (two years after entry)

Digital Rectal Examination (DRE) results

T2 (two years after entry)
T3 PSA Screening Results
Zeitfenster: T3 (three years after entry)

Prostate-Specific Antigen (PSA) result

T3 (three years after entry)
T3 DRE Screening Results
Zeitfenster: T3 (three years after entry)

Digital Rectal examination (DRE) result

T3 (three years after entry)
T4 PSA Screening Result
Zeitfenster: T4 (four years after entry)

Prostate-Specific Antigen (PSA) result

T4 (four years after entry)
T5 PSA Screening Results
Zeitfenster: T5 (five years after entry)

Prostate-Specific Antigen (PSA) result.

T5 (five years after entry)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Christine D Berg, National Cancer Institute (NCI)

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

16. November 1993

Primärer Abschluss (Tatsächlich)

21. Mai 2012

Studienabschluss (Geschätzt)

30. Juni 2027

Studienanmeldedaten

Zuerst eingereicht

1. November 1999

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

25. März 2004

Zuerst gepostet (Geschätzt)

26. März 2004

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

18. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

17. November 2026

Zuletzt verifiziert

1. Juli 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • NCI-2012-01755
  • CDR0000078532
  • NCI-P93-0050
  • PLCO-1
  • NCI-2012-01755 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
  • PLCO-Prostate (Andere Kennung: National Cancer Institute)

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .